Local
Rakuten Medical Initiates First-in-Human Phase 1 Trial of PD-L1-Targeted RM-0256 Photoimmunotherapy in Japan
Meet in Common connects news with real conversations. Use ThinkMatch to arrange a Roundtable and meet people to discuss this story.
Roundtables are designed for groups of four, with a shared subject and room for everyone to speak. Come for discussion, with no dating expectation.
Source: Union

Preclinical studies suggest that RM-0256 photoimmunotherapy may target PD-L1-expressing tumor and immunosuppressive cells and inhibit PD-L1/PD-1 interaction, potentially inducing local and systemic antitumor immune responses
This excerpt comes from the named source. Read the original for the full reporting.
Read the original at Union



